A Recommendation to Oncologists for Cancer Treatment by Immunotherapy: Quantitative and Qualitative Analysis

Today, the treatment of cancer, in a relatively short
period, with minimum adverse effects is a great concern for
oncologists. In this paper, based on a recently used mathematical
model for cancer, a guideline has been proposed for the amount
and duration of drug doses for cancer treatment by immunotherapy.
Dynamically speaking, the mathematical ordinary differential
equation (ODE) model of cancer has different equilibrium points;
one of them is unstable, which is called the no tumor equilibrium
point. In this paper, based on the number of tumor cells an
intelligent soft computing controller (a combination of fuzzy logic
controller and genetic algorithm), decides regarding the amount
and duration of drug doses, to eliminate the tumor cells and
stabilize the unstable point in a relatively short time. Two different
immunotherapy approaches; active and adoptive, have been studied
and presented. It is shown that the rate of decay of tumor cells is
faster and the doses of drug are lower in comparison with the result
of some other literatures. It is also shown that the period of
treatment and the doses of drug in adoptive immunotherapy are
significantly less than the active method. A recommendation to
oncologists has also been presented.

Authors:

• Mandana Kariminejad
• Ali Ghaffari

Keywords:

• Tumor
• immunotherapy
• fuzzy controller
• Genetic algorithm
• mathematical model.

References:

[1] Araujo, R.P. and McElwain, D.S., 2004. A history of the study of solid
tumour growth: the contribution of mathematical modelling. Bulletin of
mathematical biology, 66(5), pp.1039-1091.
[2] Enderling, H., Chaplain, M.A., Anderson, A.R. and Vaidya, J.S., 2007.
A mathematical model of breast cancer development, local treatment
and recurrence. Journal of theoretical biology, 246(2), pp.245- 259.
[3] Sachs, R.K., Hlatky, L.R. and Hahnfeldt, P., 2001. Simple ODE models
of tumor growth and anti- angiogenic or radiation treatment.
Mathematical and Computer Modelling, 33(12-13), pp.1297-1305.
[4] Anderson, A.R., Chaplain, M.A., Newman, E.L., Steele, R.J. and Thompson, A.M., 2000. Mathematical modelling of tumour invasion
and metastasis. Computational and Mathematical Methods in Medicine,
2(2), pp.129-154.
[5] Swanson, K.R., Bridge, C., Murray, J.D. and Alvord, E.C., 2003.
Virtual and real brain tumors: using mathematical modeling to quantify
glioma growth and invasion. Journal of the neurological sciences,
216(1), pp.1-10.
[6] Szymańska, Z., 2003. Analysis of immunotherapy models in the context
of cancer dynamics. International Journal of Applied Mathematics and
Computer Science, 13(3), pp.407-418.
[7] O'Byrne, K.J., Dalgleish, A.G., Browning, M.J., Steward, W.P. and
Harris, A.L., 2000. The relationship between angiogenesis and the
immune response in carcinogenesis and the progression of
malignant disease. European journal of cancer, 36(2), pp.151-169.
[8] Stewart, T.H., 1996. Immune Mechanisms and Tumor Dormancy.
Revista Medicina, 56(1), p.
[9] Restifo, N.P., Dudley, M.E. and Rosenberg, S.A., 2012. Adoptive
immunotherapy for cancer: harnessing the T cell response. Nature
Reviews Immunology, 12(4), p.269.
[10] de Pillis, L.G., Gu, W. and Radunskaya, A.E., 2006. Mixed
immunotherapy and chemotherapy of tumors: modeling, applications
and biological interpretations. Journal of theoretical biology,
238(4), pp.841-862.
[11] Pena-Reyes, C.A. and Sipper, M., 1999. A fuzzy-genetic approach to
breast cancer diagnosis. Artificial intelligence in medicine, 17(2),
pp.131-155.
[12] Swierniak, A., Kimmel, M. and Smieja, J., 2009. Mathematical
modeling as a tool for planning anticancer therapy. European journal of
pharmacology, 625(1-3), pp.108-121.
[13] Itik, M., Salamci, M.U. and Banks, S.P., 2010. SDRE optimal control of
drug administration in cancer treatment. Turkish Journal of Electrical
Engineering & Computer Sciences, 18(5), pp.715- 730.
[14] Burden, T.N., Ernstberger, J. and Fister, K.R., 2004. Optimal control
applied to immunotherapy. Discrete and Continuous Dynamical
Systems Series B, 4(1), pp.135-146.
[15] Ghaffari, A. and Naserifar, N., 2010. Optimal therapeutic protocols in
cancer immunotherapy. Computers in biology and medicine, 40(3),
pp.261-270.
[16] Vignard, V., Lemercier, B., Lim, A., Pandolfino, M.C., Guilloux, Y.,
Khammari, A., Rabu, C., Echasserieau, K., Lang, F., Gougeon, M.L.
and Dreno, B., 2005. Adoptive transfer of tumor- reactive Melan-Aspecific
CTL clones in melanoma patients is followed by increased
frequencies of additional Melan-A-specific T cells. The Journal of
Immunology, 175(7), pp.4797-4805.